Skip to content

Intravenous Iron May Increase Depression Among Hemodialysis Patients

Intravenous Iron May Increase Depression Among Hemodialysis Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03157050
Enrollment
112
Registered
2017-05-17
Start date
2016-01-14
Completion date
2017-05-16
Last updated
2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Hemodialysis Complication, Iron Deficiency Anemia

Brief summary

the aim of this study is to assess whether increased ferritin after intravenous iron therapy will lead to increased prevalence of major depression among treated patients.

Interventions

each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses

Sponsors

New Jeddah Clinic Hospital
CollaboratorINDUSTRY
Benha University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. age was above 19 years, 2. patient on maintenance hemodialysis, 3. patient had iron deficiency anemia (ferritin \> 100 ng/ml)

Exclusion criteria

1. patient has history of depression or already using antidepressant medication, 2. Lack of ferritin level increase ≥ 50% from baseline level before IV iron administration, 3. patient already on oral or intravenous iron supplement

Design outcomes

Primary

MeasureTime frameDescription
Change in patient health questionnaire-9 scoreon day 0 of start of intravenous iron and 1 week after completion of intravenous ironchange in patient health questionnaire-9 score before and after intravenous iron therapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026